Vincristine

Generic Name: Vincristine

Brand Names: Marqibo, Vincasar

Drug Type: Small Molecule

Chemical Formula: C_₄₆H_₅₆N_₄O_₁₀

CAS Number: 57-22-7

Unique Ingredient Identifier: 5J49Q6B70F

Background: Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...

Indication: Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma

Associated Therapies: -

Clinical Trials

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Phase 2

Not yet recruiting

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
T Acute Lymphoblastic Leukemia

Interventions: Drug: Asparaginase Erwinia chrysanthemi
Procedure: Biospecimen Collection
Procedure: Bone Marrow Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Etoposide
Biological: Filgrastim
Biological: Pegfilgrastim
Procedure: Positron Emission Tomography
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine

First Posted Date: 2024-12-17

Last Posted Date: 2024-12-17

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT06738368

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Phase 1

Not yet recruiting

Conditions: Refractory Solid Tumors
Relapsed Solid Tumors
Relapsed Neuroblastoma
Refractory Neuroblastoma
Relapsed Rhabdomyosarcoma
Refractory Rhabdomyosarcoma

Interventions: Drug: PEEL-224
Drug: Vincristine
Drug: Temozolomide (TMZ)

First Posted Date: 2024-12-06

Last Posted Date: 2024-12-06

Lead Sponsor: Theodore Laetsch

Target Recruit Count: 59

Registration Number: NCT06721689

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Phase 3

Not yet recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Biological: Zilovertamab vedotin
Biological: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Biological: Rituximab Biosimilar
Drug: Prednisone
Drug: Prednisolone
Drug: Vincristine

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1046

Registration Number: NCT06717347

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination with Vincristine and Temozolomide in Adolescents and Young Adults with Relapsed or Refractory Sarcomas

Phase 1

Not yet recruiting

Conditions: Sarcoma
Sarcoma, Ewing
Osteosarcoma
Rhabdomyosarcoma
Desmoplastic Small Round Cell Tumor
Refractory Sarcoma

Interventions: Drug: PEEL-224
Drug: Temozolomide
Drug: Vincristine
Biological: Pegfilgrastim
Biological: Filgrastim

First Posted Date: 2024-11-28

Last Posted Date: 2024-11-28

Lead Sponsor: David S Shulman, MD

Target Recruit Count: 63

Registration Number: NCT06709495

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

Phase 2

Recruiting

Conditions: Follicular Lymphoma

Interventions: Radiation: radiation therapy
Drug: Tiselizumab
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2024-11-26

Last Posted Date: 2024-11-26

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 20

Registration Number: NCT06704555

Locations: 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China

Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

Phase 2

Not yet recruiting

Conditions: Marginal Zone Lymphoma(MZL)

Interventions: Drug: Orelabrutinib
Drug: rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Prednisone tablet

First Posted Date: 2024-11-22

Last Posted Date: 2024-11-22

Lead Sponsor: Fei Li

Target Recruit Count: 90

Registration Number: NCT06700798

Locations: 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2

Not yet recruiting

Conditions: Lymphoma
Peripheral T Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Interventions: Drug: Tazemetostat
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Cytoxan
Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-18

Lead Sponsor: Eric Jacobsen, MD

Target Recruit Count: 24

Registration Number: NCT06692452

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States